Harvard Bioscience director granted 16,556 RSUs

Snider William reported acquisition or exercise transactions in this Form 4 filing.

Rhea-AI Filing Summary

Snider William reported acquisition or exercise transactions in this Form 4 filing.

Harvard Bioscience director William Snider received an equity grant in the form of 16,556 restricted stock units of common stock. The award vests in full immediately before the company’s next annual meeting or one year from the grant date, whichever occurs first, providing time-based compensation for board service.

After this grant, Snider holds a total of 48,556 common share equivalents, including the new award, previously purchased common shares from March 16 and March 17, 2026, and 11,000 restricted stock units scheduled to fully vest on December 17, 2026. The filing also notes that the 11,000 restricted stock units were adjusted to reflect a 10-for-1 reverse stock split that took place on March 13, 2026.

Insider Trade Summary

Grant/Award: 16,556 shares

Grant/Award 1 txn

Insider Snider William

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	16,556	$0.00	$0.00

Holdings After Transaction: Common Stock — 48,556 shares (Direct)

Footnotes (3)

1. F1. Represents an award of 16,556 restricted stock units that vests in full (i) immediately prior to the Company's next annual meeting; or (ii) one year from the date of grant, whichever is earlier.
2. F2. Includes (a) the award described in footnote (1) above, (b) 12,525 shares of common stock purchased on March 16, 2026, (c) 8,475 shares of common stock purchased on March 17, 2026, and (d) 11,000 restricted stock units that fully vest on December 17, 2026.
3. F3. On March 13, 2026, the common stock of Harvard Bioscience, Inc. underwent a reverse stock split in a ratio of 10-for-1. The 11,000 restricted stock units referenced in Footnote 2(d) were previously reported as covering 110,000 restricted stock units. This number has been adjusted to reflect the stock split that occurred on March 13, 2026.

Key Figures

RSUs granted: 16,556 units Grant price: $0.00 per share Total holdings after grant: 48,556 shares/units +3 more

6 metrics

RSUs granted 16,556 units Restricted stock unit award to director on June 9, 2026

Grant price $0.00 per share Compensation grant, not open-market purchase

Total holdings after grant 48,556 shares/units Common share equivalents following the reported transaction

Previously purchased shares 12,525 + 8,475 shares Common stock purchases on March 16 and March 17, 2026

Unvested RSUs 11,000 units Restricted stock units vesting on December 17, 2026

Reverse stock split ratio 10-for-1 Reverse split of common stock on March 13, 2026

Key Terms

restricted stock units, annual meeting, reverse stock split, 10-for-1, +1 more

5 terms

restricted stock units financial

"Represents an award of 16,556 restricted stock units that vests in full..."

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

annual meeting financial

"...vests in full (i) immediately prior to the Company's next annual meeting..."

A company's annual meeting is a yearly gathering where owners (shareholders) and the board review performance, ask questions, and vote on key matters like electing directors, approving auditor choices, and sometimes setting pay or dividend policies. For investors it matters because decisions made and votes cast can change who runs the company, influence strategy and payouts, and affect the value or direction of their investment—similar to a homeowners’ meeting where rules and leaders that shape your property’s value are decided.

reverse stock split financial

"On March 13, 2026, the common stock of Harvard Bioscience, Inc. underwent a reverse stock split in a ratio of 10-for-1."

A reverse stock split reduces a company's number of outstanding shares while raising the price per share proportionally, so the total value of each investor's holding is unchanged; a 1-for-10 split turns 100 shares worth $1 each into 10 shares worth $10 each. Companies often do this to regain compliance with an exchange's minimum price rule or to attract investors who avoid very low-priced stocks.

10-for-1 financial

"...underwent a reverse stock split in a ratio of 10-for-1."

common stock financial

"Includes (a) the award described in footnote (1) above, (b) 12,525 shares of common stock..."

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Harvard Bioscience (HBIO) director William Snider report on this Form 4?

William Snider reported receiving 16,556 restricted stock units of Harvard Bioscience common stock as a grant. These units are part of his director compensation and increase his total holdings, combining both stock awards and previously purchased shares.

How and when do William Snider’s new restricted stock units in HBIO vest?

The 16,556 restricted stock units vest in full either immediately before Harvard Bioscience’s next annual meeting or one year from the grant date, whichever happens first. Until vesting, the units represent a right to receive shares subject to service-based conditions.

What are William Snider’s total reported holdings in Harvard Bioscience after this transaction?

After the grant, Snider’s total reported holdings are 48,556 common share equivalents. This figure includes the new restricted stock units, common shares purchased on March 16 and March 17, 2026, and 11,000 restricted stock units vesting on December 17, 2026.

Was there a stock split affecting William Snider’s HBIO restricted stock units?

Yes. On March 13, 2026, Harvard Bioscience completed a 10-for-1 reverse stock split. As a result, 11,000 restricted stock units now reported were previously shown as 110,000 units, and the number was adjusted to reflect the split ratio.

Did William Snider buy or sell any Harvard Bioscience shares in the market in this filing?

The filing reports an acquisition coded as a grant of 16,556 restricted stock units with a price of $0.00 per share, reflecting compensation rather than a market trade. Prior open-market purchases on March 16 and 17, 2026 are referenced only in the footnotes.

What does the zero price on William Snider’s HBIO restricted stock unit grant indicate?

The $0.00 price indicates these 16,556 restricted stock units were granted as compensation, not purchased in the open market. Such awards typically vest over time and then convert into common shares without the director paying an exercise price.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/11/2026 - 12:56 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Snider William

(Last) (First) (Middle)

C/O HARVARD BIOSCIENCE, INC.

84 OCTOBER HILL ROAD

(Street)

HOLLISTON MASSACHUSETTS

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
HARVARD BIOSCIENCE INC [ HBIO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/09/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/09/2026		A		16,556(1)	A	$0.00	48,556(2)(3)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents an award of 16,556 restricted stock units that vests in full (i) immediately prior to the Company's next annual meeting; or (ii) one year from the date of grant, whichever is earlier.

2. Includes (a) the award described in footnote (1) above, (b) 12,525 shares of common stock purchased on March 16, 2026, (c) 8,475 shares of common stock purchased on March 17, 2026, and (d) 11,000 restricted stock units that fully vest on December 17, 2026.

3. On March 13, 2026, the common stock of Harvard Bioscience, Inc. underwent a reverse stock split in a ratio of 10-for-1. The 11,000 restricted stock units referenced in Footnote 2(d) were previously reported as covering 110,000 restricted stock units. This number has been adjusted to reflect the stock split that occurred on March 13, 2026.

	/s/ William Snider	06/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)